Inclusion of populations at risk of advanced melanoma in an opportunistic targeted screening project involving general practitioners

References

• Curiel-Lewandrowski C, Kim CC, Swetter SM, et al. Survival is not the only valuable end point in melanoma screening. J Invest Dermatol. 2012;132:1332–1337.
   PubMed Web of Science ®Google Scholar
• Piris A, Lobo AC, Duncan LM. Melanoma staging: where are we now? Dermatol Clin. 2012;30:581–592.
   PubMed Web of Science ®Google Scholar
• Grange F, Barbe C, Aubin F, et al. Clinical and sociodemographic characteristics associated with thick melanomas: a population-based, case-case study in France. Arch Dermatol. 2012;17:1–7.
   Google Scholar
• Weyers W. The ‘epidemic’ of melanoma between under- and overdiagnosis. J Cutan Pathol. 2012;39:9–16.
   PubMed Web of Science ®Google Scholar
• Lyratzopoulos G, Abel GA, Brown CH, et al. Socio-demographic inequalities in stage of cancer diagnosis: evidence from patients with female breast, lung, colon, rectal, prostate, renal, bladder, melanoma, ovarian and endometrial cancer. Ann Oncol. 2013;24:843–850.
   PubMed Web of Science ®Google Scholar
• Birch-Johansen F, Hvilsom G, Kjaer T, et al. Social inequality and incidence of and survival from malignant melanoma in a population-based study in Denmark, 1994–2003. Eur J Cancer. 2008;44:2043–2049.
   PubMed Web of Science ®Google Scholar
• Rutherford MJ, Ironmonger L, Ormiston-Smith N, et al. Estimating the potential survival gains by eliminating socioeconomic and sex inequalities in stage at diagnosis of melanoma. Br J Cancer. 2015;31:S116–S123.
   Web of Science ®Google Scholar
• Van Durme DJ, Ferrante JM, Pal N, et al. Demographic predictors of melanoma stage at diagnosis. Arch Fam Med. 2000;9:606–611.
   PubMedGoogle Scholar
• Mandalà M, Imberti GL, Piazzalunga D, et al. Association of socioeconomic status with Breslow thickness and disease-free and overall survival in stage I–II primary cutaneous melanoma. Mayo Clin Proc. 2011;86:113–119.
   PubMed Web of Science ®Google Scholar
• Geller AC, Swetter SM, Oliveria S, et al. Reducing mortality in individuals at high risk for advanced melanoma through education and screening. J Am Acad Dermatol. 2011;65:S87–S94.
   Web of Science ®Google Scholar
• Andrulonis R, Secrest AM, McGuire ST, et al. The influence of age and sex on reasons for seeking and expected benefits of skin cancer screening. Arch Dermatol. 2010;146:1097–1102.
   PubMedGoogle Scholar
• Merseyside and Cheshire Cancer Network. Targeting men aged 50+ to increase early detection of melanoma local campaign planning guide. [Internet]; [cited 2014 Nov 1] Available from: http://info.cancerresearchuk.org/prod_consump/groups/cr_common/@nre/@hea/documents/generalcontent/cr_045568.pdf (accessed 1 Nov 2014).
   Google Scholar
• Rat C, Quereux G, Riviere C, et al. Targeted melanoma prevention intervention: a cluster-randomized controlled trial. Ann Fam Med. 2014;12:21–28.
   PubMed Web of Science ®Google Scholar
• Rat C, Quereux G, Grimault C, et al. Melanoma incidence and patient compliance in a targeted melanoma screening intervention. One-year follow-up in a large French cohort of high-risk patients. Eur J Gen Pract. 2015;21:124–130.
   PubMed Web of Science ®Google Scholar
• Quéreux G, N’guyen JM, Cary M, et al. Validation of the Self-Assessment of Melanoma Risk Score for a melanoma-targeted screening. Eur J Cancer Prev. 2012;21:588–595.
   PubMed Web of Science ®Google Scholar
• Cokkinides VE, Geller AC, Jemal A. Trends in melanoma mortality among non-Hispanic whites by educational attainment, 1993–2007. Arch Dermatol. 2012;148:587–591.
   PubMedGoogle Scholar
• Boxer P, Wilson S, Mathers N. Short report: how often do UK primary care trials face recruitment delays? Fam Pract. 2007;24:601–603.
   PubMed Web of Science ®Google Scholar
• Van der Wouden JC, Blankenstein AH, Huibers MJ, et al. Survey among 78 studies showed that Lasagna's law holds in Dutch primary care research. J Clin Epidemiol. 2007;60:819–824.
   PubMed Web of Science ®Google Scholar
• Montella M, Crispo A, Grimaldi M, et al. An assessment of factors related to tumor thickness and delay in diagnosis of melanoma in southern Italy. Prev Med. 2002;35:271–277.
   PubMed Web of Science ®Google Scholar
• Richard MA, Grob JJ, Avril MF, et al. Delays in diagnosis and melanoma prognosis (I): the role of patients. Int J Cancer. 2000;89:271–279.
   PubMed Web of Science ®Google Scholar
• Baumert J, Plewig G, Volkenandt M, et al. Factors associated with a high tumour thickness in patients with melanoma. Br J Dermatol. 2007;156:938–944.
   PubMed Web of Science ®Google Scholar
• Gonzalez EC, Ferrante JM, Van Durme DJ, et al. Comorbid illness and the early detection of cancer. South Med J. 2001;94:913–920.
   PubMed Web of Science ®Google Scholar
• McCarney R, Warner J, Iliffe S, et al. The Hawthorne effect: a randomised controlled trial. BMC Med Res Methodol. 2007;7:30.
   PubMed Web of Science ®Google Scholar
• Simon AE, Waller J, Robb K, et al. Patient delay in presentation of possible cancer symptoms: the contribution of knowledge and attitudes in a population sample from the United Kingdom. Cancer Epidemiol Biomarkers Prev. 2010;19:2272–2277.
   PubMed Web of Science ®Google Scholar
• Bränström R, Kristjansson S, Ullén H. Risk perception, optimistic bias, and readiness to change sun related behaviour. Eur J Public Health. 2006;16:492–497.
   PubMed Web of Science ®Google Scholar
• Hvidberg L, Pedersen AF, Wulff CN, et al. Cancer awareness and socio-economic position: results from a population-based study in Denmark. BMC Cancer. 2014;14:581.
   PubMed Web of Science ®Google Scholar
• Falk M, Magnusson H. Sun protection advice mediated by the general practitioner: an effective way to achieve long-term change of behaviour and attitudes related to sun exposure? Scand J Prim Health Care. 2011;29:135–143.
   PubMed Web of Science ®Google Scholar
• Søgaard M, Thomsen RW, Bossen KS, et al. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013;5:3–29.
   PubMedGoogle Scholar
• Kundu RV. Practice gaps. Barriers in melanoma detection in ethnic minorities: comment on anatomic distribution of malignant melanoma on the non-Hispanic black patient, 1998–2007. Arch Dermatol. 2012;148:801–802.
   PubMedGoogle Scholar
• Fleming ST, Pursley HG, Newman B, et al. Comorbidity as a predictor of stage of illness for patients with breast cancer. Med Care. 2005;43:132–140.
   PubMed Web of Science ®Google Scholar
• Roetzheim RG, Lee JH, Ferrante JM, et al. The influence of dermatologist and primary care physician visits on melanoma outcomes among medicare beneficiaries. J Am Board Fam Med. 2013;26:637–647.
   PubMed Web of Science ®Google Scholar
• Stitzenberg KB, Thomas NE, Dalton K, et al. Distance to diagnosing provider as a measure of access for patients with melanoma. Arch Dermatol. 2007;143:991–998.
   PubMedGoogle Scholar
• O’Keefe DJ, Jensen JD. The relative persuasiveness of gain-framed and loss-framed messages for encouraging disease detection behaviors: a meta-analytic review. J Health Commun. 2007;12:623–644.
   PubMed Web of Science ®Google Scholar
• Gallagher KM, Updegraff JA. Health message framing effects on attitudes, intentions, and behavior: a meta-analytic review. Ann Behav Med. 2012;43:101–116.
   PubMed Web of Science ®Google Scholar
• Camilloni L, Ferroni E, Cendales BJ, et al. Methods to increase participation Working Group, et al. Methods to increase participation in organised screening programs: a systematic review. BMC Public Health. 2013;13:464.
   PubMed Web of Science ®Google Scholar
• Royal College of Physicians: trust in professions 2008: public awareness of trust in professions. London; 2008.
   Google Scholar
• Raine R, Duffy SW, Wardle J, et al. Impact of general practice endorsement on the social gradient in uptake in bowel cancer screening. Br J Cancer. 2016;114:321–326.
   PubMed Web of Science ®Google Scholar